The European Commission (EC) has signed an agreement with Pfizer and its German partner BioNTech to deliver additional four million doses of vaccine against coronavirus by the end of March, Report informs referring to TASS.
"The European Commission has reached an agreement with BioNTech-Pfizer for the supply of four million more doses of COVID-19 vaccines for Member States in the next two weeks in order to tackle coronavirus hotspots and to facilitate free border movement," reads the statement.
The hotspots mean regions where the number of infections and hospitalizations has sharply increased in recent weeks, which has led to the adoption of tough measures by member states and even, in some cases, the introduction of new border controls.
The European Commission has signed contracts for the supply of vaccines from six European and US manufacturers, of which three received and commissioned the approval of the European Medicines Agency (EMA): the US-German Pfizer-BioNTech consortium, the US company Moderna and the UK-Swedish AstraZeneca.
On Feb. 17, the EC announced that it had approved a second contract with Moderna to supply additional 300 million doses of vaccine against coronavirus.